DDW 2018: IBD Study Updates
This article summarises some of the key study updates presented at DDW 2018.
This article summarises some of the key study updates presented at DDW 2018.
Professor John Lafrate (Harvard Medical School, Boston) and Professor Frank Detterbeck (Yale School of Medicine, New Haven) spoke in a session looking at some of the difficulties with diagnosis and… read more.
First-line treatment with the PD-1 inhibitor pembrolizumab showed an overall survival benefit compared to platinum-based chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer and… read more.
With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…
Hot topics in lung cancer – interviews from ASCO 2018.
June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.
A retrospective study of outpatient records for millions of patients in the UK reveals that the overuse of broad-spectrum alternative antibiotics among patients who are probably not allergic… read more.
In addition to clinical segmentation of MM patients as young or elderly and fit or frail, genetic factors convey important prognostic information and should be taken into account… read more.
Patients with moderate-to-severe uncontrolled asthma treated with the ezcema drug dupilumab have achieved significantly lower rates of severe asthma exacerbation than those using a placebo. Researchers reported this… read more.
Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd)… read more.
The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.
When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.